Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01968785 · ClinicalTrials.gov registry record · NA
Renal Denervation in Patients With Uncontrolled Blood Pressure
A NA study, sponsored by Medstar Health Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT01968785: Clinical Trial NA study, sponsored by Medstar Health Research Institute.
NCT01968785 is a NA study that was terminated before completion, run by Medstar Health Research Institute. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01968785, a NA study, was terminated before completion, sponsored by Medstar Health Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The kidneys are an important regulator of blood pressure. Previous research has shown that disrupting the nerves (denervate) of the kidney may successfully decrease blood pressure. In the past, one technique that was used to treat severe high blood pressure was a surgical procedure to cut these nerves. However, this surgery is no longer commonly performed. Another approach to disrupting these nerves is to use the Beta-Cath 3.5F system to deliver a small amount of radiation to the treatment zone. The Beta-Cath 3.5F System (Novoste) is currently approved in the United States to deliver ion dose therapy to re-narrowings that form in the coronary arteries in the heart. This trial is assessing the safety of treating patients with the Beta-Cath 3.5F System (Novoste) to denervate the nerves around the kidney to help control blood pressure in patients with uncontrolled hypertension. 1. Renal artery brachytherapy with beta-emitting source is safe. 2. Renal artery brachytherapy with beta-emitting source can reduce systolic/diastolic blood pressure via renal denervation mechanism within 6 months post treatment.
Primary Outcome
The primary safety endpoint for renal artery brachytherapy with beta-emitting source is any need for renal artery intervention to treat renal artery injury induced by the catheter of radiation within 6 months
Interventions
- RADIATION Radiation Dose 25 Gy
- RADIATION Radiation Dose 50 Gy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-08 |
| Est. Completion | 2017-01 |
| Phase | NA |
Why NCT01968785 stopped before completion
NCT01968785 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Radiation Dose 25 Gy is the first listed.
NCT01968785 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01968785 about?
NCT01968785 is a clinical study titled "Renal Denervation in Patients With Uncontrolled Blood Pressure". The kidneys are an important regulator of blood pressure. Previous research has shown that disrupting the nerves (denervate) of the kidney may successfully decrease blood pressure. In the past, one technique that was used to treat severe high blood pressure was a surgical procedure to cut these nerv...
What is the current status of trial NCT01968785?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2013-08. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01968785?
The interventions under investigation include: Radiation Dose 25 Gy (RADIATION), Radiation Dose 50 Gy (RADIATION).
Who is sponsoring clinical trial NCT01968785?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01968785's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia